PAKINAX is a pre-clinical oncology research company with a proprietary technology platform focused on discovering and developing kinase inhibitors for specific kinases involved in cancers and unmet medical needs.

Our platform enables us to discover new chemical entities (NCEs) in a de novo fashion with the desired degree of potency, specificity and selectivity. We have successfully utilized this platform to discover PKX227 which is a highly selective kinase inhibitor that can be used for chemotherapy and immunotherapy for pancreatic cancer.